| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 环(苯丙氨酸-羟脯氨酸)二肽; Cyclo(Phe-Hpro) | CFN90280 | 1016899-94-7 | C14H16N2O3 = 260.30 | 10mg | QQ客服：1413575084 |
| 环(脯氨酸-亮氨酸)二肽; Cyclo(Pro-Leu) | CFN90281 | 5654-86-4 | C11H18N2O2 = 210.27 | 10mg | QQ客服：1457312923 |
| 环(脯氨酸-丙氨酸)二肽; Cyclo(Pro-Ala) | CFN90282 | 65556-33-4 | C8H12N2O2 = 168.20 | 10mg | QQ客服：3257982914 |
| 环(亮氨酸-丙氨酸)二肽; Cyclo(Leu-Ala) | CFN90283 | 1803-60-7 | C9H16N2O2 = 184.24 | 10mg | QQ客服：215959384 |
| 环(异亮氨酸-丙氨酸)二肽; Cyclo(Ile-Ala) | CFN90284 | 90821-99-1 | C9H16N2O2 = 184.24 | 10mg | QQ客服：1457312923 |
| 环(羟脯氨酸-亮氨酸)二肽; Cyclo(Hpro-Leu) | CFN90285 | 1016899-93-6 | C11H18N2O3 = 226.27 | 10mg | QQ客服：2056216494 |
| 环(苯丙氨酸-甘氨酸)二肽; Cyclo(Phe-Gly) | CFN90286 | 5037-75-2 | C11H12N2O2 = 204.23 | 10mg | QQ客服：2159513211 |
| 环(酪氨酸-亮氨酸)二肽; Cyclo(Tyr-Leu) | CFN90287 | 82863-65-8 | C15H20N2O3 = 276.33 | 10mg | QQ客服：215959384 |
| 环(亮氨酸-亮氨酸)二肽; Cyclo(Leu-Leu) | CFN90288 | 1436-27-7 | C12H22N2O2 = 226.32 | 10mg | QQ客服：1413575084 |
| 环(异亮氨酸-亮氨酸)二肽; Cyclo(Ile-Leu) | CFN90289 | 91741-17-2 | C12H22N2O2 = 226.32 | 10mg | QQ客服：3257982914 |
| 环-(亮氨酸-缬氨酸)二肽; Cyclo(Leu-Val) | CFN90291 | 5625-50-3 | C11H20N2O2 = 212.29 | 10mg | QQ客服：215959384 |
| 9-氨基喜树碱; 9-Aminocamptothecin | CFN90309 | 91421-43-1 | C20H17N3O4 = 363.37 | 20mg | QQ客服：1413575084 |
| 马兜铃内酰胺I; Aristololactam I | CFN90312 | 13395-02-3 | C17H11NO4 = 293.27 | 20mg | QQ客服：1413575084 |
| 硫酸马钱子碱; Brucine sulfate | CFN90316 | 4845-99-2 | C46H54N4O12S = 887.01 | 20mg | QQ客服：2159513211 |
| 酒石酸长春质碱; Catharanthine Tartrate | CFN90318 | 2648-21-5 | C21H24N2O2.C4H6O6 = 486.40 | 20mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)